UCLA conference. Interferon: immunobiology and clinical significance.
Interferons are proteins elaborated by infected cells that protect noninfected cells from viral infection. These proteins produce a temporary "antiviral state" by altering nucleotide metabolism and cytoplasmic enzyme induction. Interferons appear early after viral infection locally and systematically to limit spread of viral infection; they also affect cell differentiation, growth, surface, antigen expression, morphologic findings, and immunoregulation. Several human disorders have diminished interferon production. Newborns have normal interferon alpha but deficient interferon gamma production. Infants with congenital infections may also have defects in interferon production. Immunosuppressed patients receiving transplants (marrow, heart, of kidney) have diminished interferon production, particularly immediately after transplant. Deficiencies of interferon have also been noted in Down's syndrome, cellular immunodeficiencies, uremia, malnutrition, and hematopoietic malignancy. Leukocyte interferon has been of therapeutic value in herpes zoster infections, in patients with cancer, and in patients with hepatitis B infection. Interferon has not been proved to help children with congenital cytomegalovirus or rubella. Interferon can shrink lymphoid tumors, particularly non-Hodgkin's lymphoma.
D000818:Animals; D000917:Antibody Formation; D002454:Cell Differentiation; D002455:Cell Division; D002462:Cell Membrane / Q000276:immunology / Q000378:metabolism; D004790:Enzyme Induction; D006801:Humans; D007111:Immunity, Cellular; D007113:Immunity, Innate; D007153:Immunologic Deficiency Syndromes / Q000276:immunology; D007231:Infant, Newborn; D007372:Interferons / Q000276:immunology* / Q000502:physiology / Q000627:therapeutic use; D051379:Mice; D009369:Neoplasms / Q000628:therapy; D014181:Transplantation Immunology; D014777:Virus Diseases / Q000276:immunology / Q000628:therapy
D007372:Interferons